Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Daniel G. Welch

Daniel G. Welch is recorded as Board Member at Prothena Corp Public Ltd Co (PRTA) and Board Member at Ultragenyx Pharmaceutical Inc. (RARE). Daniel G. Welch was last confirmed as Board Member at Nuvation Bio Inc. (NUVB) in a filing dated July 30, 2024. Ultragenyx Pharmaceutical Inc. reported in an 8-K filed May 18, 2026 that Daniel G. Welch was appointed Class I Director, effective May 14, 2026. Prothena Corp Public Ltd Co reported in an 8-K filed February 21, 2024 that Daniel G. Welch was appointed director, effective February 21, 2024. Ultragenyx Pharmaceutical Inc. reported in an 8-K filed June 13, 2023 that Daniel G. Welch was appointed Class I Director, effective June 7, 2023.

“At the Annual Meeting, the Company's stockholders elected the Class I director nominees below to the Company's Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected.”
Ultragenyx Pharmaceutical Inc. Form 8-K, filed May 18, 2026 · Read the filing
“On February 21, 2024, the Board of Directors (the "Board") of Prothena Corporation plc (the "Company") increased the size of the Board and appointed Daniel G. Welch to serve as a director of the Company, effective immediately.”
Prothena Corp Public Ltd Co Form 8-K, filed February 21, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Prothena Corp Public Ltd Co

Other people whose current roles at this company are on record from its filings.

Leadership on record at Ultragenyx Pharmaceutical Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.